A microfluidic platform integrated with field-effect transistors for enumeration of circulating tumor cells

Lab on a Chip ◽  
2019 ◽  
Vol 19 (4) ◽  
pp. 618-625 ◽  
Author(s):  
Yi-Hong Chen ◽  
Anil Kumar Pulikkathodi ◽  
Yu-Dong Ma ◽  
Yu-Lin Wang ◽  
Gwo-Bin Lee

A new integrated microfluidic system was developed for automatic detection and enumeration of CTCs with field-effect transistors (FETs).

Lab on a Chip ◽  
2018 ◽  
Vol 18 (19) ◽  
pp. 2917-2925 ◽  
Author(s):  
Hong-Lin Cheng ◽  
Chien-Yu Fu ◽  
Wen-Che Kuo ◽  
Yen-Wen Chen ◽  
Yi-Sin Chen ◽  
...  

A novel microfluidic platform for extracellular vesicle extraction, microRNA isolation and detection with field-effect transistors for early detection of cardiovascular diseases.


PLoS ONE ◽  
2018 ◽  
Vol 13 (12) ◽  
pp. e0208385 ◽  
Author(s):  
Anca Ciurte ◽  
Cristina Selicean ◽  
Olga Soritau ◽  
Rares Buiga

2020 ◽  
Vol 59 (28) ◽  
pp. 11240-11244
Author(s):  
Ling‐Ling Wu ◽  
Zhi‐Ling Zhang ◽  
Man Tang ◽  
Dong‐Liang Zhu ◽  
Xiao‐Juan Dong ◽  
...  

2018 ◽  
Vol 115 (40) ◽  
pp. 9986-9991 ◽  
Author(s):  
Manjima Dhar ◽  
Jeffrey Nam Lam ◽  
Tonya Walser ◽  
Steven M. Dubinett ◽  
Matthew B. Rettig ◽  
...  

Tumor cells are hypothesized to use proteolytic enzymes to facilitate invasion. Whether circulating tumor cells (CTCs) secrete these enzymes to aid metastasis is unknown. A quantitative and high-throughput approach to assay CTC secretion is needed to address this question. We developed an integrated microfluidic system that concentrates rare cancer cells >100,000-fold from 1 mL of whole blood into ∼50,000 2-nL drops composed of assay reagents within 15 min. The system isolates CTCs by size, exchanges fluid around CTCs to remove contaminants, introduces a matrix metalloprotease (MMP) substrate, and encapsulates CTCs into microdroplets. We found CTCs from prostate cancer patients possessed above baseline levels of MMP activity (1.7- to 200-fold). Activity of CTCs was generally higher than leukocytes from the same patient (average CTC/leukocyte MMP activity ratio, 2.6 ± 1.5). Higher MMP activity of CTCs suggests active proteolytic processes that may facilitate invasion or immune evasion and be relevant phenotypic biomarkers enabling companion diagnostics for anti-MMP therapies.


Sign in / Sign up

Export Citation Format

Share Document